FDA OKs COMIRNATY XFG Vaccine as Pfizer’s Post‑Pandemic Focus Reframes
Pfizer and BioNTech previously received FDA approval for their COMIRNATY XFG mRNA COVID-19 vaccine for the 2026–2027 season, tailored to the XFG variant. U.S. distribution for adults 65+ and high-risk people ages 5–64 begins shortly after approval, helping sustain COVID revenues, though oncology execution and cost discipline remain central amid U.S. drug pricing pressure and a patent cliff.